The emerging challenge of optimal blood pressure management and hypertensive syndromes in pregnant women with sickle cell disease: a review

ABSTRACT

Introduction: Sickle cell disease (SCD) is one of the most common hemoglobinopathy, affecting a considerable proportion of black populations of African origin, Middle East and in the Indian sub-continent. Women with SCD are more likely to experience adverse pregnancy and delivery outcomes. Hypertensive diseases in pregnancy such as preeclampsia and eclampsia are more common in women with sickle cell disease.

Areas covered: This review examined the influence of hypertension and SCD in pregnancy, and provides the preliminary evidence that the traditional systolic and diastolic blood pressure thresholds for hypertensive disorders such as pre-eclampsia and eclampsia may require reassessment in pregnant women with SCD. The causes of maternal and perinatal morbidity and mortality, hypertensive complications of pregnancy in women with and without sickle cell disease were reviewed. A MEDLINE database search using medical subject headings (MeSH) and keywords for articles regarding sickle cell disease, pregnancy and hypertension was performed.

Expert commentary: Pregnancy in women with sickle cell disease is associated with high maternal and perinatal morbidity and mortality. Using the existing thresholds for diagnosis and treatment for hypertensive disease in pregnancy without adjustment to accommodate for the lower systolic and diastolic blood pressure in those with sickle cell disease may worsen an already poor maternal and perinatal outcome in this population.

KEYWORDS:

• Eclampsia
• HELLP syndrome
• hypertension
• hypertensive disorders
• preeclampsia
• pregnancy
• sickle cell disease
• SCD

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was not funded.